Stryker Co. (NYSE:SYK) Shares Sold by Mutual of America Capital Management LLC

Mutual of America Capital Management LLC cut its stake in Stryker Co. (NYSE:SYK) by 2.7% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 41,191 shares of the medical technology company’s stock after selling 1,122 shares during the period. Mutual of America Capital Management LLC’s holdings in Stryker were worth $14,831,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also bought and sold shares of SYK. Arkadios Wealth Advisors lifted its stake in Stryker by 23.0% during the 3rd quarter. Arkadios Wealth Advisors now owns 732 shares of the medical technology company’s stock valued at $265,000 after acquiring an additional 137 shares during the period. Strategic Blueprint LLC lifted its stake in Stryker by 5.8% during the 3rd quarter. Strategic Blueprint LLC now owns 1,426 shares of the medical technology company’s stock valued at $515,000 after acquiring an additional 78 shares during the period. Mutual Advisors LLC lifted its stake in Stryker by 9.0% during the 3rd quarter. Mutual Advisors LLC now owns 5,562 shares of the medical technology company’s stock valued at $2,002,000 after acquiring an additional 457 shares during the period. SteelPeak Wealth LLC lifted its stake in Stryker by 7.3% during the 3rd quarter. SteelPeak Wealth LLC now owns 796 shares of the medical technology company’s stock valued at $288,000 after acquiring an additional 54 shares during the period. Finally, US Bancorp DE lifted its stake in Stryker by 1.3% during the 3rd quarter. US Bancorp DE now owns 181,849 shares of the medical technology company’s stock valued at $65,697,000 after acquiring an additional 2,301 shares during the period. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Stryker Price Performance

Shares of NYSE SYK opened at $386.55 on Friday. The firm has a market cap of $147.50 billion, a PE ratio of 49.81, a PEG ratio of 2.93 and a beta of 0.96. The firm has a fifty day moving average of $380.50 and a 200 day moving average of $370.92. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.32 and a current ratio of 1.95. Stryker Co. has a one year low of $314.93 and a one year high of $406.19.

Stryker (NYSE:SYK) last released its earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same quarter last year, the business earned $3.46 earnings per share. As a group, research analysts predict that Stryker Co. will post 13.47 EPS for the current fiscal year.

Stryker Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st will be issued a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.87%. The ex-dividend date of this dividend is Monday, March 31st. Stryker’s payout ratio is 43.30%.

Analyst Ratings Changes

Several analysts have commented on SYK shares. Argus set a $450.00 price objective on shares of Stryker in a research note on Monday, February 3rd. Barclays lifted their target price on shares of Stryker from $418.00 to $443.00 and gave the company an “overweight” rating in a report on Monday, February 10th. Morgan Stanley raised shares of Stryker from an “equal weight” rating to an “overweight” rating and lifted their target price for the company from $370.00 to $445.00 in a report on Monday, December 2nd. Citigroup reaffirmed a “buy” rating and set a $450.00 target price on shares of Stryker in a report on Wednesday. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $442.00 target price on shares of Stryker in a report on Wednesday, January 29th. Five analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company. According to data from MarketBeat.com, Stryker has an average rating of “Moderate Buy” and an average price target of $422.15.

Insider Transactions at Stryker

In other news, Director Ronda E. Stryker sold 201,392 shares of the business’s stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the transaction, the director now owns 3,642,075 shares of the company’s stock, valued at approximately $1,428,567,498. The trade was a 5.24 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Allan C. Golston sold 2,458 shares of the business’s stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $383.07, for a total transaction of $941,586.06. Following the transaction, the director now directly owns 14,895 shares in the company, valued at approximately $5,705,827.65. The trade was a 14.16 % decrease in their position. The disclosure for this sale can be found here. Insiders own 5.90% of the company’s stock.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.